Skip to main content
Cathay Biotech Inc. logo

Cathay Biotech Inc. — Investor Relations & Filings

Ticker · 688065 ISIN · CNE100004447 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 753 across all filing types
Latest filing 2024-02-01 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688065

About Cathay Biotech Inc.

https://www.cathaybiotech.com/

Cathay Biotech Inc. specializes in the research, development, and commercial-scale production of bio-based materials through synthetic biology and metabolic engineering. The company’s core portfolio features long-chain diacids (LCDA), bio-based pentanediamine, and high-performance bio-based polyamides, including the Terryl and Ecopent product lines. These materials are utilized across various applications such as automotive components, electronics, consumer goods, and specialized textiles. By leveraging biological manufacturing processes to replace traditional thermochemical methods, the company provides sustainable alternatives to petroleum-derived chemicals. Cathay Biotech focuses on delivering high-performance, low-carbon solutions that support the transition toward a circular economy and reduced environmental impact in global supply chains.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司及招商证券股份有限公司关于上海凯赛生物技术股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from two securities companies (CITIC Securities and China Merchants Securities) regarding the listing and circulation of certain restricted shares of Shanghai Kaisa Biotechnology Co., Ltd. It references regulatory approvals, share issuance details, lock-up periods, shareholder commitments, and compliance with relevant laws and stock exchange rules. The document is not a financial report, earnings release, or management discussion but rather a formal verification and compliance opinion related to share listing and circulation. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory compliance and verification announcement that does not constitute a financial report or other specific filing type.
2024-02-01 Chinese
天健会计师事务所（特殊普通合伙）关于上海凯赛生物技术股份有限公司申请向特定对象发行股票的审核问询函中有关财务事项的说明（豁免版）
Regulatory Filings
2024-01-30 Chinese
上海市锦天城律师事务所关于上海凯赛生物技术股份有限公司2023年度向特定对象发行A股股票的补充法律意见书（一）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a specific issuance of A shares by Shanghai Kaisa Biotechnology Co., Ltd. in 2023. It discusses the legal aspects of a private placement to specific investors, including the structure of the issuance, control and governance implications, funding sources, and compliance with regulatory requirements. The document references regulatory rules, shareholder structure changes, and cooperation agreements. It is a legal opinion related to a capital raising event, specifically a private placement of shares to certain investors. This fits the category of a Capital/Financing Update (CAP), as it provides detailed legal and structural information about a financing transaction rather than being a full financial report, audit report, or other types of filings. The document length and content confirm it is not a brief announcement or a certification but a substantive legal opinion on a financing event.
2024-01-30 Chinese
关于向特定对象发行A股股票申请文件的审核问询函回复及募集说明书等申请文件更新的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Shanghai Kaisai Biotechnology Co., Ltd. regarding the response to an inquiry letter from the Shanghai Stock Exchange about the company's application to issue A-shares to specific investors. It mentions updates to the prospectus and the ongoing review process by regulatory bodies (Shanghai Stock Exchange and China Securities Regulatory Commission). The document is short (1067 characters) and primarily serves as a notice about the submission and update of application documents rather than the documents themselves. It does not contain financial statements or detailed financial data. Therefore, it is an announcement related to capital raising activities but not the actual financing report or prospectus. According to the classification rules, such a document is best classified as a Capital/Financing Update (CAP).
2024-01-30 Chinese
关于以集中竞价交易方式回购公司股份的进展暨公司“提质增效重回报”行动方案的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from Shanghai Kaisa Bio-Technology Co., Ltd. regarding the progress of the company's share repurchase program through centralized bidding transactions. It details the number of shares repurchased, prices, total funds used, and the company's plans and commitments related to the share buyback. The document references regulatory rules about share repurchases and provides updates on the ongoing buyback activity. It does not contain financial statements or quarterly/annual results but focuses on the share repurchase progress and related corporate actions. Therefore, this document fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2024-01-30 Chinese
中信证券股份有限公司及招商证券股份有限公司关于上海凯赛生物技术股份有限公司向特定对象发行A股股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" (Listing Sponsorship Letter) related to the issuance of A shares by Shanghai Cathay Biotech Co., Ltd. It contains detailed information about the issuer, the issuance plan, pricing, risk factors, financial data, and the role of the sponsor (CITIC Securities). The document is a comprehensive filing related to a capital raising event through a specific share issuance to designated investors. It is not a general annual report, earnings release, or management report. It is a formal document supporting a capital market transaction, specifically a share issuance and listing sponsorship. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed substantive information about the issuance, not merely an announcement or a brief summary, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2024-01-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.